Physiological Data Expansion Versus Clinical Efficacy in Continuous Glucose Monitoring

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.2772  
Dr. Justin A. Dower  et al.

Points

University of Gothenburg researchers synthesized clinical evidence evaluating continuous glucose monitor utility across type 2 diabetes and non-diabetic consumer populations.
Continuous glucose monitoring in type 2 diabetes provided modest glycated hemoglobin reductions and minimized hypoglycemia risks without demonstrating long-term disease prevention.
Scientific evidence failed to demonstrate any health improvements or disease prevention benefits when continuous glucose monitors were utilized by individuals without diabetes.
Normal physiological blood glucose fluctuations detected by consumer monitors risk overinterpretation, leading to unnecessary dietary restrictions and patient anxiety.
Asymptomatic individuals seeking clinical interpretation for continuous monitor readings risk diverting finite healthcare resources and time away from high-need patient populations.

Summary

The clinical efficacy, indications, and population-level implications of continuous glucose monitoring (CGM) across diverse clinical groups. Initially developed for type 1 diabetes, CGM application has expanded rapidly to type 2 diabetes and non-diabetic consumer populations. Led by Minna Johansson at Sahlgrenska Academy, University of Gothenburg, the synthesis examined whether expanded CGM usage translates to measurable disease prevention or health optimization.

In patients with type 2 diabetes, the review established that CGM use confers clinical utility by facilitating treatment adjustments, lowering the risk of severe hypoglycemia, and achieving modest mean reductions in glycated hemoglobin (HbA1c). However, no scientific evidence demonstrates that CGM implementation prevents macrovascular or microvascular disease outcomes in this group. For individuals without diabetes, the authors identified no scientific evidence indicating that CGM usage improves overall health, prevents metabolic disease, or yields clinical benefits.

The researchers caution that commercial marketing of consumer CGMs risks overinterpreting physiological glycemic fluctuations, driving unnecessary dietary restriction and patient anxiety. Furthermore, healthy individuals presenting to primary care to interpret complex CGM metrics divert finite healthcare resources from high-risk populations. The authors emphasize that clinical utilization of CGM technology should remain grounded in proven clinical efficacy rather than data availability or commercial expansion.

Link to the article: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2851941

References

Dower, J. A., Johansson, M., Camp, A. W., Montori, V. M., & Lipska, K. J. (2026). Continuous glucose monitoring in type 2 diabetes and beyond: A review. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.2772